Alirocumab Subcutaneous Injection 75 mg/mL and 150 mg/mL Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous Injection
Available Strengths: 75 mg/mL and 150 mg/mL
Reference Brands: Praluent(US & EU)
Category: Heart Disorder
Alirocumab is a monoclonal antibody that inhibits PCSK9, increasing LDL receptor availability to enhance LDL cholesterol clearance from the blood. It effectively lowers LDL levels, reducing cardiovascular risk. Benefits include significant LDL reductions, improved heart health, and prevention of atherosclerotic events in high-risk patients.
Product Description: Alirocumab, marketed as Praluent, is approved in the US by the FDA and in the EU via EMA for lowering LDL cholesterol in patients with familial hypercholesterolemia or cardiovascular risk. Regulatory approval requires a comprehensive dossier including clinical trial data, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical and quality data to ensure safety and efficacy, while the EMA evaluates regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regulatory adherence supports timely approval, safe use, and global availability of alirocumab subcutaneous injections, contributing to improved cardiovascular health worldwide.
Alirocumab Subcutaneous Injection — third party manufacturing & bulk supply
Alirocumab Subcutaneous Injection 75 mg/mL and 150 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Alirocumab Subcutaneous Injection is supplied as Subcutaneous Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Alirocumab Subcutaneous Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Alirocumab Subcutaneous Injection →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Trandolapril
Strength:
0.5 mg, 1 mg, 2 mg
Form: Tablets
Reference Brands: Mavik (USA), Gopten (EU)
View Details
Tirofiban Hydrochloride
Strength:
2.5 mg/mL
Form: Injection
Reference Brands: Aggrastat (USA)
View Details
Selexipag
Strength:
200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg
Form: Tablets / Injection
Reference Brands: Uptravi (USA/EU)
View Details
Edoxaban
Strength:
15 mg, 30 mg, 60 mg
Form: Tablets
Reference Brands: Savaysa (USA), Lixiana (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
